中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2015年
11期
112-113
,共2页
5-羟色胺再摄取抑制剂%抑郁症%安全性
5-羥色胺再攝取抑製劑%抑鬱癥%安全性
5-간색알재섭취억제제%억욱증%안전성
5- serotonin reuptake inhibitors%Depression%Safety
目的：探究SSRIS(5-羟色胺再摄取抑制剂)类药物在治疗抑郁症时的临床效果与用药安全性。方法将该院收治的150例抑郁症患者为研究对象，对所有患者进行SSRIS药物治疗，按照治疗药物的不同分为西酞普兰组、帕罗西汀组、氟西汀组，持续治疗12周，观察患者的病情改善情况。结果不同类型的SSRIS药物在治疗结束的12周帕罗西汀组表现出的改善抑郁症状明显优于氟西汀组(<0.05)；3组患者在治疗后的第四周西酞普兰组及帕罗西汀组相比氟西汀组在提高患者工作适应情况及社会功能上更为显著(<0.05)；而3组患者在治疗过程中并未发生严重的不良反应，且各组间的不良反应差异无统计学意义(>0.05)。结论 SSRIS类药物对于抑郁症患者的临床症状能快速进行控制，安全性可靠，对于需要快速控制病情的抑郁症患者可将SSRIS类药物作为首选。
目的：探究SSRIS(5-羥色胺再攝取抑製劑)類藥物在治療抑鬱癥時的臨床效果與用藥安全性。方法將該院收治的150例抑鬱癥患者為研究對象，對所有患者進行SSRIS藥物治療，按照治療藥物的不同分為西酞普蘭組、帕囉西汀組、氟西汀組，持續治療12週，觀察患者的病情改善情況。結果不同類型的SSRIS藥物在治療結束的12週帕囉西汀組錶現齣的改善抑鬱癥狀明顯優于氟西汀組(<0.05)；3組患者在治療後的第四週西酞普蘭組及帕囉西汀組相比氟西汀組在提高患者工作適應情況及社會功能上更為顯著(<0.05)；而3組患者在治療過程中併未髮生嚴重的不良反應，且各組間的不良反應差異無統計學意義(>0.05)。結論 SSRIS類藥物對于抑鬱癥患者的臨床癥狀能快速進行控製，安全性可靠，對于需要快速控製病情的抑鬱癥患者可將SSRIS類藥物作為首選。
목적：탐구SSRIS(5-간색알재섭취억제제)류약물재치료억욱증시적림상효과여용약안전성。방법장해원수치적150례억욱증환자위연구대상，대소유환자진행SSRIS약물치료，안조치료약물적불동분위서태보란조、파라서정조、불서정조，지속치료12주，관찰환자적병정개선정황。결과불동류형적SSRIS약물재치료결속적12주파라서정조표현출적개선억욱증상명현우우불서정조(<0.05)；3조환자재치료후적제사주서태보란조급파라서정조상비불서정조재제고환자공작괄응정황급사회공능상경위현저(<0.05)；이3조환자재치료과정중병미발생엄중적불량반응，차각조간적불량반응차이무통계학의의(>0.05)。결론 SSRIS류약물대우억욱증환자적림상증상능쾌속진행공제，안전성가고，대우수요쾌속공제병정적억욱증환자가장SSRIS류약물작위수선。
Objective To explore clinical effect of SSRIS (5- serotonin reuptake inhibitors) drugs in the treatment and the safety of drug use. Methods 150 cases patients with depression in our hospital were selected as the research subjects, all patients used SSRIS drugs, accoring to differencet methods of treament, patients were dvided into citalopram group, paroxitine group, fluoxetine group, who were treated with SSRIS drug continuous treatment for 12 weeks,patients condition in three groups were observed. ResultsAt the end of the treatment of 12 weeks,use different types of SSRIS drugs,paroxetine group showed the improvement of the depressive symptoms obviously better than that of fluoxetine group(<0.05);at the end of the treatment of 4 weeks,citalopram group and paroxetine group compared with fluoxetine group on improving work adapt to the situation and the social function in patients with more pronounced (<0.05);and the three group of patients in the course of treatment did not happen serious adverse events, three groups of adverse reaction were no significant difference (<0.05) . Conclusion SSRIS drugs for clinical symptom in patients with depression can quickly control, safety and reliable, the need for rapid control of the disease in patients with depression can be SSRIS drugs as the preferred.
